Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.49 |
| ▸ | RELA | Q04206 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783880 | 0.88 | BTK (0.51) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL471719 | 0.88 | BTK (0.49) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL471720 | 0.88 | BTK (0.49) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL508784 | 0.88 | BTK (0.49) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL763965 | 0.84 | NFKB1 (0.49) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4270316 | 0.84 | NFKB1 (0.49) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL20063806 | 0.84 | NFKB1 (0.49) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4270314 | 0.84 | NFKB1 (0.49) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL21294876 | 0.84 | NFKB1 (0.49) | BTKNFKB1NFKB2RELAEPHX2 | |
| SCHEMBL31650782 | 0.81 | BTK (0.47) | BTKNFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116023945-B | Etching liquid composition, etching liquid and preparation method thereof | 浙江奥首材料科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-116023945-A | Etching liquid composition, etching liquid and preparation method thereof | 浙江奥首材料科技有限公司 | 2023-04-28 | — | — | CN | claimed |
| EP-4709389-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4577520-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025133989-A1 | SMYD MODULATORS AND USES THEREOF | ALT-BIO PTE. LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024233747-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | CELGENE CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-26 | — | — | US | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-116023945-B | Etching liquid composition, etching liquid and preparation method thereof | 浙江奥首材料科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2008042353-A1 | POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-1670478-A2 | HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7037916-B2 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050107369-A1 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-05-19 | — | — | US | disclosed |
| WO-2005026111-A2 | HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004062609-A2 | PYRIMIDINE DERIVATIVES AS IL-8 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA, LLC | 2004-05-06 | — | — | US | disclosed |
| US-5998398-A | HERPES VIRUS | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| CN-1212683-A | 2-amino-5,6-dichlorobenzimidazole derivatives having antiviral activity | GLAXO GROUP LTD (GB) | 1999-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107369-A1 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | BTK 4472/4885NFKB1 2529/4885NFKB2 2620/4885 |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | CXCL8, IL1RN, IL18 | BTK 1201/4885NFKB1 391/4885NFKB2 339/4885 |
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | PRMT5, PRMT1, PRMT6 | BTK 1274/4885NFKB1 1054/4885NFKB2 2493/4885 |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | BTK 63/4885NFKB1 1168/4885NFKB2 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.